In-Med Prognostics leverages deep learning algorithms and machine learning to provide time-saving accurate Neuro analysis which aids in the assessment and early detection of neurological disorders such as Dementia, Alzheimer’s and Parkinson’s at affordable prices
Artificial Intelligence (AI) firm In-Med Prognostics has raised $2.13 million led by Exxora with participation from angels. The funds will be used to stabilize and expand the product portfolio and tap global markets.
In-Med Prognostics leverages deep learning algorithms and machine learning to provide time-saving accurate Neuro analysis which aids in the assessment and early detection of neurological disorders such as Dementia, Alzheimer’s and Parkinson’s at affordable prices. Their ‘Neuroshield’ solution provides a self-explanatory volumetric report within an analysis time of 20 minutes.
The company offers AI-powered image processing proprietary software for neurologist decision support and radiologist workflow enhancement.
In-Med India was founded in 2018. It announced a Rs 50 lakh grant from BIRAC in 2019. In-Med Inc, the US holding company was formed in 2021. Since then, it secured global IP and deployed a new CT Tool. The company has also expanded to Africa, as per reported by YourStory.
Also read: Technology leaders have to always be in a learning phase
Do Follow: CIO News LinkedIn Account | CIO News Facebook | CIO News Youtube | CIO News Twitter
About us:
CIO News, a proprietary of Mercadeo, produces award-winning content and resources for IT leaders across any industry through print articles and recorded video interviews on topics in the technology sector such as Digital Transformation, Artificial Intelligence (AI), Machine Learning (ML), Cloud, Robotics, Cyber-security, Data, Analytics, SOC, SASE, among other technology topics
